Welcome to our dedicated page for Canopy Growth SEC filings (Ticker: CGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Canopy Growth Corporation (CGC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, along with AI-powered summaries that help interpret complex documents. As a Canadian issuer with common shares listed on the Nasdaq Global Select Market, Canopy Growth files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy materials with the U.S. Securities and Exchange Commission.
Current reports on Form 8-K are central to understanding material events affecting CGC stock. Recent 8-K filings describe items such as the arrangement agreement to acquire MTL Cannabis Corp., including consideration structure, conditions, and termination provisions; term loan amendments and prepayment agreements; at-the-market equity distribution arrangements; quarterly earnings releases furnished under Item 2.02; and changes in executive leadership, including the appointment of the Chief Financial Officer. Other 8-Ks report on shareholder meeting results, including director elections, auditor re-appointment, share consolidation authority, and advisory say-on-pay votes.
Periodic reports—the Form 10-K and Form 10-Q—contain detailed financial statements, segment information for cannabis and Storz & Bickel, risk factors related to the cannabis industry and regulatory environment, management’s discussion and analysis, and disclosures on liquidity, capital resources, and internal controls. These filings also incorporate risk discussions referenced in the company’s news releases, including legal and regulatory risks in Canada, Europe, Australia, and the United States.
Proxy statements on Schedule 14A outline Canopy Growth’s corporate governance framework, board composition, committee structures, and executive compensation programs. They describe director nominees, voting matters presented at the annual general and special meeting, and updates to governance policies such as the code of business conduct and ethics, disclosure policy, and insider trading policy.
On this page, Stock Titan’s tools surface new CGC filings as they appear on EDGAR and generate AI summaries that highlight key terms, covenants, and implications for shareholders. Users can quickly see the main points of a lengthy 10-K, review the core provisions of financing or acquisition agreements disclosed in 8-Ks, and identify how shareholder votes and governance changes may affect the company. Filings related to insider compensation and board decisions are also accessible through these documents.
Canopy Growth Corp director and Chief Legal Officer & Corporate Secretary Christelle Gedeon reported a sale of 16,929 common shares on 08/22/2025 at a price of CAD $1.74 per share. The filing states the disposition was made to satisfy tax obligations tied to the vesting of restricted stock units. After the sale, the reporting person beneficially owned 368,488 common shares. The Form 4 was signed by an attorney-in-fact on 08/26/2025. All amounts and the sale rationale are presented in the filing; no additional transaction types or derivative holdings are disclosed.
Christelle Gedeon, Chief Legal Officer and Corporate Secretary of Canopy Growth Corp (CGC), reported a sale of 4,528 common shares on 08/18/2025 at a price of CA$1.86 per share. The filing shows 385,417 shares beneficially owned by Ms. Gedeon after the transaction. The form states the disposition was made to satisfy tax obligations arising from the vesting of restricted stock units. The report was signed by an attorney-in-fact on behalf of the reporting person and is a routine officer disclosure under Section 16.
Canopy Growth Corp (CGC) reported a grant of 45,680 restricted stock units to director M. Shan Atkins on August 12, 2025. The RSUs were issued as compensation and will vest in three scheduled tranches: 10,578 RSUs on September 29, 2025, 17,551 RSUs on December 31, 2025, and 17,551 RSUs on March 31, 2026. The filing shows the reporting person is a director and the transaction was reported as an acquisition at no cash price. The Form 4 was signed by an attorney-in-fact on August 14, 2025, and provides the standard disclosure of beneficial ownership following the grant.
Form 3 filing by a company director reports no ownership. Margaret Shan Atkins filed an initial Form 3 as a director of Canopy Growth Corporation (CGC) for the event dated
Canopy Growth Corporation filed a Form 8-K dated 8 Aug 2025. Under Item 2.02, the company furnished (not filed) a press release detailing fiscal Q1 FY26 results for the quarter ended 30 Jun 2025; the actual financial figures are contained in Exhibit 99.1 and are not included in this filing.
Under Item 5.02, the board appointed Margaret Shan Atkins as an independent director, effective 6 Aug 2025, and named her to the audit committee. The filing states there are no related-party transactions, and Ms. Atkins will receive standard director compensation and a customary indemnification agreement. No other material events, transactions or guidance updates are disclosed.
CGC Q1 FY26 (quarter ended 30 Jun 2025) highlights:
- Net revenue rose 9% YoY to CA$72.1 m (CA$66.2 m LY) as adult-use, medical and accessories sales grew.
- Gross margin fell to 25% (CA$18.0 m) from 35% (CA$23.0 m) on higher COGS and CA$1.9 m inventory write-downs.
- Operating loss narrowed to CA$22.6 m vs. CA$29.1 m; net loss improved sharply to CA$41.5 m (CA$129.2 m LY) as prior-year period contained CA$93.9 m fair-value and debt-settlement charges.
- Cash burn: operating cash outflow cut to CA$10.3 m (CA$51.8 m). FCF benefited from lower restructuring and working-capital release.
- Liquidity: cash & equivalents up to CA$126.2 m (CA$113.8 m at Mar-25) aided by CA$38.3 m raised under Feb-25 ATM program. Short-term investments CA$17.4 m.
- Leverage: total debt reduced to CA$295.3 m (CA$304.1 m), with current portion CA$6.3 m. Credit-facility balance shrank after ongoing discounted repurchases.
- Equity: book value CA$489.0 m; accumulated deficit widened to CA$10.97 bn.
- Canopy USA deconsolidated (effective Apr-24) creating CA$5.0 m gain and recognition of equity-method investments and CA$142.4 m Elevate loan receivable.
- Management states substantial-doubt concerns are "alleviated" via equity raises, debt pay-downs and ongoing cost actions, but continues to evaluate further financing.
Per-share: basic loss CA$0.22 vs CA$1.60 as share count rose to 188.3 m (79.2 m LY) due to ATM and acquisition-related issuances.
Canopy Growth’s 2025 DEF 14A outlines four voting items for the 26-Sep-2025 virtual AGM:
- Election of five directors (four incumbents plus new nominee Joe Bayern). Independent directors would remain 80% of the board; David Lazzarato continues as independent chair.
- Re-appointment of PKF O’Connor Davies LLP as auditor for FY 2026.
- A special resolution authorising a 5-for-1 to 15-for-1 reverse share split at the board’s discretion before 26-Sep-2026 to restore compliance with stock-exchange price requirements.
- Advisory “say-on-pay” approval of FY 2025 executive compensation.
Governance & policy highlights: the board refreshed seven key policies (Disclosure, Insider-Trading, Regulation FD, Anti-Bribery, Clawback, Code of Business Conduct, Disclosure Compliance) and offered four director-education sessions.
Compensation: New CEO Luc Mongeau’s package—C$975k salary, 100% STI target, 300% LTI mix (50% options/50% RSUs) plus a one-time 225k option/50k RSU sign-on grant—reflects a scaled structure versus former CEO David Klein, whose salary was cut to US$750k and whose outstanding equity will be forfeited on retirement (31-Aug-2025). FY 2025 NEO cash bonuses paid at 77.6% of target as only 17.6% of EBITDA and 29.3% of revenue targets were met.
Shareholder logistics: record date 1-Aug-2025; proxies due 24-Sep-2025. All participation and voting will be via live audio webcast.
FAQ
What is the current stock price of Canopy Growth (CGC)?
What is the market cap of Canopy Growth (CGC)?
